FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2278907595> ?p ?o ?g. }

• W2278907595 endingPage "19556" @default.
• W2278907595 startingPage "19556" @default.
• W2278907595 abstract "19556 Background: Rash develops in approximately 90% of patients (pts) treated with epidermal growth factor receptor inhibitors (EGFRIs) E and C, leading to significant physical/psychosocial discomfort and inconsistent therapy. This study characterizes outcomes of a rash management algorithm developed in the multidisciplinary dermatology-oncology SERIES clinic. Methods: Retrospective chart analysis was performed of pts with E and C rashes (n=45) who were treated with: oral tetracyclines (doxycycline or minocycline) bid and topical calcineurin inhibitors (pimecrolimus/ tacrolimus) or corticosteroids bid. After a baseline visit, pts were assessed at 2–4 week intervals and CTC graded (G). Management data, skin biopsies and photographs were evaluated. Response was defined as: Complete Response (CR) = severity decrease (decr) by 2G, Partial Response (PR) = 1G decr, Stable Disease (SD) = no G change, and Progressive Disease (PD) = increase by = 1G. Best response (BR) was defined as the patient’s best rash outcome at any point in time. Results: 43 out of 45 pts had evaluable data. Of 27 women and 16 men, mean age = 60 yrs (range 34–88), 60% received E and 40% C. For BR, 51% of patients had a CR, 42% had PR, 7% had SD, and 0% had PD. Age was related to BR (p=0.036), with median ages (in years) of 66, 57.5 and 48 for 22, 18 and 3 pts with CR, PR and SD respectively. BR was related to grade (p=0.045), with CR in 69% of G1 pts, 35% in G2 pts, and 54% in G3 pts. BR was not related to E or C (p=0.40). Dose modification was required in 8% (E) and 22% (C) and dose discontinuation in 0% (E) and 17% (C) pts. Conclusions: SERIES algorithm rash management demonstrates that combined oral tetracyclines, topical calcineurin inhibitors and corticosteroids result in improvement in a majority of subjects. The greater rate of dose modification/discontinuation with C supports the need for proactive/early intervention. Trials are underway to evaluate prophylactic therapies against rash to EGFRIs. No significant financial relationships to disclose." @default.
• W2278907595 created "2016-06-24" @default.
• W2278907595 creator A5013908866 @default.
• W2278907595 creator A5015349477 @default.
• W2278907595 creator A5021374000 @default.
• W2278907595 creator A5022205095 @default.
• W2278907595 creator A5037456539 @default.
• W2278907595 creator A5052379457 @default.
• W2278907595 creator A5059298173 @default.
• W2278907595 creator A5071727468 @default.
• W2278907595 creator A5078803884 @default.
• W2278907595 date "2007-06-20" @default.
• W2278907595 modified "2023-09-27" @default.
• W2278907595 title "Management of rash to erlotinib (E) and cetuximab (C): Results from the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinaseS) clinic algorithm" @default.
• W2278907595 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.19556" @default.
• W2278907595 hasPublicationYear "2007" @default.
• W2278907595 type Work @default.
• W2278907595 sameAs 2278907595 @default.
• W2278907595 citedByCount "1" @default.
• W2278907595 countsByYear W22789075952017 @default.
• W2278907595 crossrefType "journal-article" @default.
• W2278907595 hasAuthorship W2278907595A5013908866 @default.
• W2278907595 hasAuthorship W2278907595A5015349477 @default.
• W2278907595 hasAuthorship W2278907595A5021374000 @default.
• W2278907595 hasAuthorship W2278907595A5022205095 @default.
• W2278907595 hasAuthorship W2278907595A5037456539 @default.
• W2278907595 hasAuthorship W2278907595A5052379457 @default.
• W2278907595 hasAuthorship W2278907595A5059298173 @default.
• W2278907595 hasAuthorship W2278907595A5071727468 @default.
• W2278907595 hasAuthorship W2278907595A5078803884 @default.
• W2278907595 hasConcept C121608353 @default.
• W2278907595 hasConcept C126322002 @default.
• W2278907595 hasConcept C128057223 @default.
• W2278907595 hasConcept C141071460 @default.
• W2278907595 hasConcept C16005928 @default.
• W2278907595 hasConcept C2776028589 @default.
• W2278907595 hasConcept C2778087573 @default.
• W2278907595 hasConcept C2778570526 @default.
• W2278907595 hasConcept C2779438470 @default.
• W2278907595 hasConcept C2780580887 @default.
• W2278907595 hasConcept C2911091166 @default.
• W2278907595 hasConcept C71924100 @default.
• W2278907595 hasConcept C90924648 @default.
• W2278907595 hasConceptScore W2278907595C121608353 @default.
• W2278907595 hasConceptScore W2278907595C126322002 @default.
• W2278907595 hasConceptScore W2278907595C128057223 @default.
• W2278907595 hasConceptScore W2278907595C141071460 @default.
• W2278907595 hasConceptScore W2278907595C16005928 @default.
• W2278907595 hasConceptScore W2278907595C2776028589 @default.
• W2278907595 hasConceptScore W2278907595C2778087573 @default.
• W2278907595 hasConceptScore W2278907595C2778570526 @default.
• W2278907595 hasConceptScore W2278907595C2779438470 @default.
• W2278907595 hasConceptScore W2278907595C2780580887 @default.
• W2278907595 hasConceptScore W2278907595C2911091166 @default.
• W2278907595 hasConceptScore W2278907595C71924100 @default.
• W2278907595 hasConceptScore W2278907595C90924648 @default.
• W2278907595 hasIssue "18_suppl" @default.
• W2278907595 hasLocation W22789075951 @default.
• W2278907595 hasOpenAccess W2278907595 @default.
• W2278907595 hasPrimaryLocation W22789075951 @default.
• W2278907595 hasRelatedWork W123703021 @default.
• W2278907595 hasRelatedWork W1983751091 @default.
• W2278907595 hasRelatedWork W1998366229 @default.
• W2278907595 hasRelatedWork W1999410809 @default.
• W2278907595 hasRelatedWork W2070232725 @default.
• W2278907595 hasRelatedWork W2125304050 @default.
• W2278907595 hasRelatedWork W2357703221 @default.
• W2278907595 hasRelatedWork W2907669593 @default.
• W2278907595 hasRelatedWork W3029694895 @default.
• W2278907595 hasRelatedWork W3034543458 @default.
• W2278907595 hasVolume "25" @default.
• W2278907595 isParatext "false" @default.
• W2278907595 isRetracted "false" @default.
• W2278907595 magId "2278907595" @default.
• W2278907595 workType "article" @default.